NASDAQ · RZLTHealthcarePharmaceuticals

Rezolute, Inc. Common Stock (NV) financials

$4.09−2.15%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY26
Jun 30
FY25
Jun 30
FY24
Jun 30
FY23
Jun 30
FY21
Jun 30
Revenue$0.00$0.00$0.00$0.00—
Gross profit$0.00$0.00$0.00$0.00—
Gross margin—————
Operating income-$83.0M-$79.9M-$70.4M-$56.0M-$22.9M
Net income-$77.6M-$74.4M-$68.5M-$51.8M-$20.9M
Net margin—————
Diluted EPS$-0.75$-0.98$-1.33$-1.01$-2.72
EBITDA-$82.9M-$79.9M-$70.4M-$56.0M-$22.9M
Operating cash flow-$64.6M-$69.1M-$57.4M-$44.5M-$20.4M
Free cash flow-$64.6M-$69.1M-$57.4M-$44.6M—
Diluted shares103.9M76.0M51.5M51.2M7.7M

Balance sheet

Period endJun 30Jun 30Jun 30Jun 30Jun 30Jun 30
Cash & equivalents$10.6M$94.1M$70.4M$16.0M$150.4M$41.0M
Short-term investments$97.2M$73.8M$56.5M$85.9M——
Total debt$0.00$0.00$0.00$0.00$0.00$14.0M
Total assets$112.8M$175.5M$132.7M$123.7M$152.4M$42.6M
Total liabilities$12.2M$13.4M$11.7M$7.5M$2.9M$16.5M
Shareholders' equity$100.7M$162.1M$121.0M$116.2M$149.5M$26.1M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology